ArticleFrontiers in immunology2025
Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Successful Treatment of Overlapping Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Glial Fibrillary Acidic Protein Astrocytopathy With Plasma Exchange.Journal of medical cases · 2026Article
- MOG-Ab-associated optic neuritis with concurrent GFAP-Ab positivity following tislelizumab-based treatment: a case report.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glial fibrillary acidic protein-immunoglobulin G (GFAP-IgG) can coexist with aquaporin-4-IgG (AQP4-IgG) or myelin oligodendrocyte glycoprotein-IgG (MOG-IgG). We aimed to investigate the clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG. Methods: We retrospectively collected data from 81 GFAP-IgG-positive patients and described and compared the clinical characteristics of those with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG. Results: (1) Among the 81 GFAP-IgG-positive patients, nine (11.1%) were positive for AQP4-IgG and seven (8.6%) were positive for MOG-IgG. The clinical manifestations of overlapping syndromes were diverse; all patients met the clinical phenotype of autoimmune GFAP astrocytopathy (A-GFAP-A) and also fulfilled the diagnostic criteria for neuromyelitis optica spectrum disorders or MOG antibody-associated disorders. Compared with the GFAP-AQP4 overlapping syndrome, the GFAP-MOG overlapping syndrome had a higher frequency of seizures (57.1% vs. 0, Conclusions: Among patients with A-GFAP-A, 20% had concurrent AQP4-IgG or MOG-IgG, exhibiting distinct clinical features that suggest a different disease phenotype driven by overlapping autoimmune mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.